JP2024524273A - マズチドの使用 - Google Patents

マズチドの使用 Download PDF

Info

Publication number
JP2024524273A
JP2024524273A JP2023579334A JP2023579334A JP2024524273A JP 2024524273 A JP2024524273 A JP 2024524273A JP 2023579334 A JP2023579334 A JP 2023579334A JP 2023579334 A JP2023579334 A JP 2023579334A JP 2024524273 A JP2024524273 A JP 2024524273A
Authority
JP
Japan
Prior art keywords
dose
drug
week
uric acid
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524273A5 (cg-RX-API-DMAC10.html
Inventor
ペイ アン
ホアン トン
Original Assignee
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス（スーチョウ）カンパニー，リミティド filed Critical イノベント バイオロジクス（スーチョウ）カンパニー，リミティド
Publication of JP2024524273A publication Critical patent/JP2024524273A/ja
Publication of JP2024524273A5 publication Critical patent/JP2024524273A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023579334A 2021-06-25 2022-06-23 マズチドの使用 Pending JP2024524273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110711050.0 2021-06-25
CN202110711050 2021-06-25
PCT/CN2022/100878 WO2022268174A1 (zh) 2021-06-25 2022-06-23 Mazdutide的应用

Publications (2)

Publication Number Publication Date
JP2024524273A true JP2024524273A (ja) 2024-07-05
JP2024524273A5 JP2024524273A5 (cg-RX-API-DMAC10.html) 2025-06-30

Family

ID=84544128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579334A Pending JP2024524273A (ja) 2021-06-25 2022-06-23 マズチドの使用

Country Status (9)

Country Link
US (1) US20240293513A1 (cg-RX-API-DMAC10.html)
EP (1) EP4360641A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524273A (cg-RX-API-DMAC10.html)
KR (1) KR20240027053A (cg-RX-API-DMAC10.html)
CN (1) CN117597135A (cg-RX-API-DMAC10.html)
AU (1) AU2022298841A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224043A1 (cg-RX-API-DMAC10.html)
TW (2) TW202617173A (cg-RX-API-DMAC10.html)
WO (1) WO2022268174A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023281591A1 (en) * 2022-06-01 2025-01-02 Innovent Biologics (Suzhou) Co., Ltd. Treatment method using mazdutide
EP4788362A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
EP4788356A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating adolescent obesity
WO2025098422A1 (zh) * 2023-11-07 2025-05-15 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521043A (ja) * 2015-06-22 2018-08-02 イーライ リリー アンド カンパニー グルカゴン及びｇｌｐ−１共アゴニスト化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
AU2023281591A1 (en) * 2022-06-01 2025-01-02 Innovent Biologics (Suzhou) Co., Ltd. Treatment method using mazdutide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521043A (ja) * 2015-06-22 2018-08-02 イーライ リリー アンド カンパニー グルカゴン及びｇｌｐ−１共アゴニスト化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SABRINA M NIELSEN ET AL.: "Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal stud", ANNALS OF THE RHEUMATIC DISEASES, vol. 76, no. 11, JPN6026025837, 2017, pages 1870 - 1882, ISSN: 0005891928 *
山中 寿: "高尿酸血症・痛風の治療ガイドライン（第2版）改訂の要点と人間ドック健診での活用", 人間ドック (NINGEN DOCK), vol. 25, no. 5, JPN6026025838, 2011, pages 765 - 770, ISSN: 0005891929 *

Also Published As

Publication number Publication date
US20240293513A1 (en) 2024-09-05
TW202300171A (zh) 2023-01-01
EP4360641A4 (en) 2025-10-22
CA3224043A1 (en) 2022-12-29
CN117597135A (zh) 2024-02-23
EP4360641A1 (en) 2024-05-01
TW202617173A (zh) 2026-05-01
AU2022298841A1 (en) 2024-01-25
WO2022268174A1 (zh) 2022-12-29
KR20240027053A (ko) 2024-02-29

Similar Documents

Publication Publication Date Title
RU2546520C2 (ru) Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
RU2583134C2 (ru) Профилактика гипогликемии у пациентов с сахарным диабетом 2 типа
TW202300171A (zh) Mazdutide的應用
US20200038488A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
CN107375909A (zh) 在2型糖尿病患者中预防低血糖症
EP2324853A1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
US20250296973A1 (en) Treatment method using mazdutide
AU2019229469B2 (en) GLP-1 composition for treating obesity and weight management
McFarlane Antidiabetic medications and weight gain: implications for the practicing physician
WO2024243243A9 (en) Treatment of adults with overweight or obesity with or without weight-related comorbidities
CN112057619A (zh) 一种具有降血糖作用的药物组合物
Roy Administration of once-daily canagliflozin to a non-diabetic patient in addition to standard aerobic exercise: a case report
HK40110048A (en) Use of mazdutide
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
AU2009238272B2 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
WO2025073289A1 (en) Methods of treating diabetes and obesity
EP4531894A1 (en) Methods of using a gcg/glp1 co-agonist for therapy
TW202140061A (zh) 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
HK40118093A (en) Treatment method using mazdutide
CA2915413C (en) Insulin glargine/lixisenatide fixed ratio formulation
JP2021528424A (ja) 対象における食後のグルコースレベルをコントロールする方法および使用
JP2011105609A (ja) メトホルミンへの付加療法を含む２型糖尿病の治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260625